{
  "url": "https://finance.yahoo.com/news/3-undiscovered-european-gems-promising-053449160.html?_guc_consent_skip=1756102753",
  "authorsByline": "Simply Wall St",
  "articleId": "d8b0791fc22e4b24b9f97e21bddd4a13",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T05:34:49+00:00",
  "addDate": "2025-08-25T06:21:30.600160+00:00",
  "refreshDate": "2025-08-25T06:21:30.600162+00:00",
  "score": 1.0,
  "title": "3 Undiscovered European Gems with Promising Potential",
  "description": "As European markets experience a modest uplift, buoyed by hopes of lower U.S. borrowing costs and a rise in business activity, investors are increasingly on the lookout for promising opportunities within the region. In such an environment, stocks that demonstrate resilience and potential for growth amidst economic shifts can be particularly appealing to those seeking undiscovered gems with promising potential.",
  "content": "As European markets experience a modest uplift, buoyed by hopes of lower U.S. borrowing costs and a rise in business activity, investors are increasingly on the lookout for promising opportunities within the region. In such an environment, stocks that demonstrate resilience and potential for growth amidst economic shifts can be particularly appealing to those seeking undiscovered gems with promising potential. Click here to see the full list of 327 stocks from our European Undiscovered Gems With Strong Fundamentals screener. Let's dive into some prime choices out of from the screener. Overview: Gubra A/S is a biotech company specializing in pre-clinical contract research and peptide-based drug discovery targeting metabolic and fibrotic diseases across Europe, North America, and internationally, with a market cap of DKK6.10 billion. Operations: Gubra generates revenue primarily through its pre-clinical contract research services and peptide-based drug discovery initiatives. The company's financial performance is highlighted by a notable net profit margin, indicating efficiency in managing its operations relative to revenue. Gubra, a biotech firm in Denmark, has caught attention with its recent financial turnaround and strategic moves. For the half-year ending June 2025, sales rocketed to DKK 2.49 billion from DKK 120.63 million a year prior, while net income surged to DKK 1.76 billion from a loss of DKK 20.14 million previously. The company is debt-free and boasts a low price-to-earnings ratio of 3.5x compared to the Danish market's average of 15.2x, indicating potential undervaluation. Despite forecasted earnings decline averaging at around -52% annually over three years, its partnership with AbbVie and promising clinical trials offer growth avenues amidst volatility in share prices recently observed over three months.\n\u2022 Gubra's strategic partnership with AbbVie could significantly boost its revenue prospects. Click here to explore the full narrative on Gubra's potential growth through this collaboration.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/b12ff78b-cf2b-46c7-95bc-2dc07a9b1c31?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/narratives/lodgakts-the-epbd-2026-implementation-will-unlock-renovation-demand-across-europe-vwas?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/discover/investing-ideas/152/undiscovered-gems-with-strong-fundamentals/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/company/id/c6e8c454-220b-48fe-a82f-77a3a3417d63?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014241",
    "https://feedback.simplywall.st/article/NDAxNDI0MTozYzYzMTI3YmNhNjRjOWRj",
    "https://simplywall.st/portfolio?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/narratives/n8m7m79d-medical-and-engineered-solutions-will-open-new-markets-usi6?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/company/id/54c067c3-08bf-4afb-8a2f-7d967c43d1ae?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014241",
    "https://simplywall.st/narratives/94ufd831-abbvie-agreement-and-clinical-trials-will-unlock-new-avenues?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "pre-clinical contract research",
      "weight": 0.08830592
    },
    {
      "name": "promising clinical trials",
      "weight": 0.08295835
    },
    {
      "name": "promising potential",
      "weight": 0.07803945
    },
    {
      "name": "lower U.S. borrowing costs",
      "weight": 0.07406303
    },
    {
      "name": "growth avenues",
      "weight": 0.07111914
    },
    {
      "name": "European markets",
      "weight": 0.07097661
    },
    {
      "name": "promising opportunities",
      "weight": 0.067299254
    },
    {
      "name": "Gubra",
      "weight": 0.06721321
    },
    {
      "name": "net income",
      "weight": 0.066598706
    },
    {
      "name": "share prices",
      "weight": 0.0654899
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.99609375
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.98291015625
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.9404296875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.64794921875
    },
    {
      "name": "/Finance/Investing/Other",
      "score": 0.6455078125
    }
  ],
  "sentiment": {
    "positive": 0.81872356,
    "negative": 0.029938724,
    "neutral": 0.15133774
  },
  "summary": "The article discusses the three European companies that have potential for growth in these areas. Gubra A/S, a Danish biotech firm specializing in pre-clinical contract research and peptide-based drug discovery, has attracted attention with its recent financial turnaround and strategic moves. Despite a forecasted earnings decline averaging at around -52% annually over three years, the company's partnership with AbbVie and promising clinical trials could significantly boost its revenue prospects. The company is debt-free and its low price-to-earth valuation indicates potential undervaluation.",
  "shortSummary": "As European markets experience a modest economic boost, investors are drawn to potential undiscovered European gems like Gubra A/S, driven by strong financial performance and strategic moves.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "26509bc18998458f8f3103967607b806",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/portfolio?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
      "text": "US$294,170\nUS$186,967\n19.7%\nUS$129,548\nUS$46,631\nUS$11,515\n-US$726\nUS$4,776\n/yr\nPortfolio\nS&P 500 (US)\nA past performer with good growth potential\n14 holdings\n14\n| Symbol | Price Vs Fair Value | 7D Return | Total Return | Value & Cost | Weight & Shares | Avg. Price | 1Y chart | |\n|---|---|---|---|---|---|---|---|---|\nXOM Exxon Mobil | US$111.28 54.5% undervalued intrinsic discount | 4.3% +US$935 | 99.5% +US$12,919 | US$22,812 US$12,897 | 7.8% 205 | US$62.91 | ||\nTLX Telix Pharmaceuticals | AU$18.33 78.7% undervalued intrinsic discount | 3.3% +US$268 | 91.6% +US$6,712 | US$8,325 US$5,128 | 2.8% 700 | AU$11.00 | ||\nBAC Bank of America | US$49.48 18.4% undervalued intrinsic discount | 3.3% +US$936 | 68.6% +US$13,108 | US$29,688 US$19,100 | 10.1% 600 | US$31.83 | ||\nJNJ Johnson & Johnson | US$179.29 26.3% undervalued intrinsic discount | 1.7% +US$152 | 88.8% +US$4,529 | US$8,965 US$5,100 | 3.0% 50 | US$102.00 | ||\nJPM JPMorgan Chase | US$296.24 15.0% undervalued intrinsic discount | 1.6% +US$236 | 47.6% +US$4,997 | US$14,812 US$10,500 | 5.0% 50 | US$210.00 | ||\nTSLA Tesla | US$340.01 170.3% overvalued intrinsic discount | 1.4% +US$485 | 53.9% +US$11,901 | US$34,001 US$22,100 | 11.6% 100 | US$221.00 | ||\nBATS British American Tobacco | UK\u00a343.15 31.3% undervalued intrinsic discount | 1.3% +US$520 | 44.5% +US$17,162 | US$40,833 US$26,990 | 13.9% 700 | UK\u00a330.00 | ||\nOKTA Okta | US$92.05 28.3% undervalued intrinsic discount | 0.7% +US$53.60 | -54.0% -US$8,636 | US$7,364 US$16,000 | 2.5% 80 | US$200.00 | ||\nUNH UnitedHealth Group | US$307.42 64.6% undervalued intrinsic discount | -0.3% -US$21.40 | -25.2% -US$2,259 | US$6,148 US$8,960 | 2.1% 20 | US$448.00 | ||\nAMZN Amazon.com | US$228.84 17.2% undervalued intrinsic discount | -1.1% -US$151 | 64.5% +US$5,357 | US$13,044 US$7,775 | 4.4% 57 | US$136.41 | ||\nCRWD CrowdStrike Holdings | US$420.55 23.5% overvalued intrinsic discount | -1.4% -US$290 | 51.6% +US$9,333 | US$21,028 US$13,100 | 7.1% 50 | US$262.00 | ||\nMETA Meta Platforms | US$754.79 28.6% undervalued intrinsic discount | -1.6% -US$1,069 | 339.1% +US$53,785 | US$64,157 US$13,830 | 21.8% 85 | US$162.71 | ||\nNVDA NVIDIA | US$177.99 54.0% overvalued intrinsic discount | -2.2% -US$161 | 870.0% +US$15,096 | US$7,120 US$1,443 | 2.4% 40 | US$36.06 | ||\nPLTR Palantir Technologies | US$158.74 107.4% overvalued intrinsic discount | -8.8% -US$1,529 | 833.8% +US$14,174 | US$15,874 US$1,700 | 5.4% 100 | US$17.00 |\nThere are three easy ways to get started:\nSimply Wall St goes far beyond price tracking. You'll be able to:\nMost brokers and portfolio trackers only show prices and unrealised gains, with little context and lots of noisy news. Simply Wall St offers:\nIn short, Simply Wall St is more than a tracker \u2014 it's a complete investing platform for monitoring, analysing, and growing your portfolio.\nHave feedback on the portfolio tool?"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014241",
      "text": "Results\n1374\nCompanies with strong growth potential, backed by optimistic outlooks both from analysts and management.\n1374 companies\nFulin Precision\nMarket Cap: CN\u00a526.5b\nEngages in the research and development, manufacture, and sale of automotive engine parts in China.\n300432\nCN\u00a515.51\n7D\n-1.1%\n1Y\n235.6%\nSynspective\nMarket Cap: JP\u00a594.5b\nDesigns, builds, and operates a fleet of synthetic aperture radar satellites (SAR) to detect and understand changes.\n290A\nJP\u00a5847.00\n7D\n-12.8%\n1Y\nn/a\nGold Circuit Electronics\nMarket Cap: NT$223.4b\nDesigns, manufactures, processes, and distributes printed circuit boards in Taiwan.\n2368\nNT$459.00\n7D\n-1.4%\n1Y\n112.5%\nFindi\nMarket Cap: AU$239.2m\nThrough its subsidiaries, engages in the development of digital payment systems in India.\nFND\nAU$3.87\n7D\n-3.5%\n1Y\n-5.1%\nNovoray\nMarket Cap: CN\u00a514.6b\nProvides industrial powder materials for various applications in China and internationally.\n688300\nCN\u00a560.54\n7D\n3.6%\n1Y\n92.9%\nLaopu Gold\nMarket Cap: HK$125.8b\nDesigns, manufactures, and sells jewelry products in Mainland China, Hong Kong, and Macau.\n6181\nHK$728.50\n7D\n-6.6%\n1Y\n686.7%\nCyclopharm\nMarket Cap: AU$108.9m\nCyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally.\nCYC\nAU$0.98\n7D\n-5.8%\n1Y\n-30.2%\nAscentage Pharma Group International\nMarket Cap: HK$33.7b\nA clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.\n6855\nHK$90.65\n7D\n5.3%\n1Y\n215.9%\nElliptic Laboratories\nMarket Cap: NOK 1.2b\nAn artificial intelligence (AI) software company, engages in the provision of AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive markets in Norway, the United States, China, South Korea, Taiwan, and Japan.\nELABS\nNOK 11.06\n7D\n-7.8%\n1Y\n-10.7%\nPharma Mar\nMarket Cap: \u20ac1.4b\nA biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally.\nPHM\n\u20ac82.45\n7D\n-2.5%\n1Y\n101.7%\nCredo Technology Group Holding\nMarket Cap: US$19.6b\nProvides various high-speed connectivity solutions for optical and electrical Ethernet, and PCIe applications in the United States, Taiwan, Mainland China, Hong Kong, and internationally.\nCRDO\nUS$114.04\n7D\n-4.0%\n1Y\n223.9%\nPropel Holdings\nMarket Cap: CA$1.3b\nOperates as a financial technology company.\nPRL\nCA$32.76\n7D\n-0.06%\n1Y\n17.4%\nCD Projekt\nMarket Cap: z\u014225.8b\nTogether its subsidiaries, engages in the development, publishing, and digital distribution of video games for personal computers and video game consoles in Poland.\nCDR\nz\u0142257.90\n7D\n1.1%\n1Y\n43.1%\nKebNi\nMarket Cap: SEK 688.7m\nDevelops, produces, and sells products and applications for stabilization, navigation, and satcom worldwide.\nKEBNI B\nSEK 2.54\n7D\n17.1%\n1Y\n76.6%\nHesai Group\nMarket Cap: US$3.1b\nThrough with its subsidiaries, engages in the development, manufacture, and sale of three-dimensional light detection and ranging solutions (LiDAR) in Mainland China, Europe, North America, and internationally.\nHSAI\nUS$23.26\n7D\n-9.1%\n1Y\n445.4%\nNewfield Resources\nMarket Cap: AU$83.7m\nEngages in the mine development, stope mining, and mineral exploration activities in Australia and Africa.\nNWF\nAU$0.089\n7D\n0%\n1Y\n-19.1%\nM31 Technology\nMarket Cap: NT$19.7b\nProvides silicon intellectual property (IP) design services in the integrated circuit industry.\n6643\nNT$472.50\n7D\n-5.9%\n1Y\n-53.2%\nImage Resources\nMarket Cap: AU$88.1m\nEngages in the production and exploration of mineral sands in Western Australia.\nIMA\nAU$0.079\n7D\n0%\n1Y\n8.2%\nVuno\nMarket Cap: \u20a9291.9b\nOperates as a medical artificial intelligence (AI) solution development company.\nA338220\n\u20a920,850.00\n7D\n4.0%\n1Y\n-44.4%\nAprilBioLtd\nMarket Cap: \u20a9474.2b\nAprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics.\nA397030\n\u20a921,050.00\n7D\n-2.3%\n1Y\n1.7%\nSuzhou Sunmun Technology\nMarket Cap: CN\u00a54.6b\nEngages in the research, production, and sale of nano-coloring materials, functional nano-dispersions, special additives, intelligent color matching systems, and electronic chemicals in China.\n300522\nCN\u00a514.24\n7D\n-0.8%\n1Y\n54.4%\nKrishna Institute of Medical Sciences\nMarket Cap: \u20b9294.8b\nProvides medical and health care services under the KIMS Hospitals brand in India.\nKIMS\n\u20b9736.80\n7D\n-1.1%\n1Y\n49.1%\nAnand Rathi Wealth\nMarket Cap: \u20b9233.0b\nProvides financial advisory, brokerage, and consultancy services in India.\nANANDRATHI\n\u20b92,806.20\n7D\n3.5%\n1Y\n55.7%\nFenix Resources\nMarket Cap: AU$227.0m\nEngages in the exploration, development, and mining of mineral tenements in Western Australia.\nFEX\nAU$0.30\n7D\n-7.6%\n1Y\n0%\nOscotec\nMarket Cap: \u20a91.2t\nOperates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.\nA039200\n\u20a932,600.00\n7D\n-5.5%\n1Y\n-18.4%\nZhejiang Leapmotor Technology\nMarket Cap: HK$99.9b\nEngages in the research and development, production, and sale of new energy vehicles in Mainland China and internationally.\n9863\nHK$71.00\n7D\n8.6%\n1Y\n249.8%\nHippo Holdings\nMarket Cap: US$844.7m\nProvides property and casualty insurance products to individuals and business customers primarily in the United States.\nHIPO\nUS$33.75\n7D\n6.7%\n1Y\n70.0%\nTechwing\nMarket Cap: \u20a91.0t\nDevelops, manufactures, sells, and services semiconductor inspection equipment in South Korea and internationally.\nA089030\n\u20a928,850.00\n7D\n-1.2%\n1Y\n-37.1%\nBinastra Corporation Berhad\nMarket Cap: RM 1.9b\nAn investment holding company, engages in general contractor and property developer, building and civil engineering works in turnkey projects in Malaysia.\nBNASTRA\nRM 1.78\n7D\n0.6%\n1Y\n44.7%\nSineng ElectricLtd\nMarket Cap: CN\u00a512.3b\nEngages in the research and development, manufacture, maintenance, and trading of power electronic products in the People's Republic of China and internationally.\n300827\nCN\u00a524.59\n7D\n-0.04%\n1Y\n12.2%\nSamyang Foods\nMarket Cap: \u20a910.7t\nEngages in the food business in South Korea and internationally.\nA003230\n\u20a91,438,000.00\n7D\n4.2%\n1Y\n187.6%\nMarinomed Biotech\nMarket Cap: \u20ac35.2m\nA biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.\nMARI\n\u20ac19.80\n7D\n1.0%\n1Y\n253.6%\nBergen Carbon Solutions\nMarket Cap: NOK 187.6m\nOperates as a clean carbon technology and materials company in Norway.\nBCS\nNOK 4.47\n7D\n-6.7%\n1Y\n-12.4%\nENGAGE XR Holdings\nMarket Cap: UK\u00a35.4m\nEngages in the development of the educational virtual reality platform.\nEXR\nUK\u00a30.01\n7D\n0%\n1Y\n17.1%\nCircus\nMarket Cap: \u20ac402.0m\nA technology company, develops and delivers autonomous solutions for the food service market.\nCA1\n\u20ac16.90\n7D\n-12.7%\n1Y\n-21.8%\nAtour Lifestyle Holdings\nMarket Cap: US$4.9b\nThrough its subsidiaries, develops lifestyle brands around hotel offerings in the People\u2019s Republic of China.\nATAT\nUS$35.73\n7D\n2.4%\n1Y\n103.9%"
    },
    {
      "url": "https://simplywall.st/narratives/lodgakts-the-epbd-2026-implementation-will-unlock-renovation-demand-across-europe-vwas?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
      "text": "Key Takeaways\n- Strategic focus on organic growth, productivity investments, and restructuring boosts margins and positions Inwido for long-term profitability and revenue expansion.\n- Strong balance sheet and reduced debt offer potential for growth through strategic mergers and acquisitions, enhancing future earnings.\n- Challenges in e-commerce, fierce price competition, and delayed project deliveries threaten Inwido's short-term profitability and long-term growth ambitions.\nCatalysts\nAbout Inwido- Through its subsidiaries, engages in development, manufacture, and sale of windows and doors.\n- Inwido's strategic focus on driving organic growth, as demonstrated by a 10% organic increase in net sales and a 13% rise in order intake, positions the company well for future revenue expansion as economic conditions improve.\n- Investments in productivity-enhancing measures are starting to bear fruit, with improvements in capacity utilization and gross margins in Scandinavia and Eastern Europe. These initiatives are likely to continue enhancing net margins over the coming quarters.\n- The improved order backlog, which increased by 19%, provides visibility and assurance for future sales and earnings growth, supporting positive revenue trajectories in the near term.\n- Strategic restructuring and efficiency measures in the e-commerce division are expected to enhance future cost efficiency and margins, bolstering long-term profitability and potentially leading to earnings growth.\n- The company's strong balance sheet and reduced net debt to EBITDA ratio (from 1.4x to 1.1x) provide significant firepower for mergers and acquisitions, potentially driving top-line growth and enhancing earnings through strategic acquisitions aligned with Inwido's goals.\nInwido Future Earnings and Revenue Growth\nAssumptions\nHow have these above catalysts been quantified?- Analysts are assuming Inwido's revenue will grow by 4.2% annually over the next 3 years.\n- Analysts assume that profit margins will increase from 6.3% today to 8.6% in 3 years time.\n- Analysts expect earnings to reach SEK 882.6 million (and earnings per share of SEK 13.66) by about August 2028, up from SEK 564.7 million today.\n- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 17.3x on those 2028 earnings, down from 18.8x today. This future PE is lower than the current PE for the GB Building industry at 27.6x.\n- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.\n- To value all of this in today's terms, we will use a discount rate of 6.53%, as per the Simply Wall St company report.\nInwido Future Earnings Per Share Growth\nRisks\nWhat could happen that would invalidate this narrative?- Inwido's e-commerce business has been negatively impacted by a sudden decline in consumer spending and lower online traffic, potentially affecting future sales and operating margins.\n- Fierce price competition in markets like Western Europe, particularly in England, is leading to pressure on profit levels and could influence net margins.\n- Adverse weather conditions and municipal budget cuts in places like Scotland have delayed project deliveries, which could affect the timing of revenue recognition and net earnings.\n- Inwido's decision to maintain high overhead costs in anticipation of future demand may not immediately align with revenue growth, impacting short-term profitability and operating margins.\n- Challenges in executing M&A strategy and facing intense competition for acquisitions could slow growth ambitions, potentially affecting long-term revenue and market expansion efforts.\nValuation\nHow have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of SEK221.667 for Inwido based on their expectations of its future earnings growth, profit margins and other risk factors.\n- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be SEK10.2 billion, earnings will come to SEK882.6 million, and it would be trading on a PE ratio of 17.3x, assuming you use a discount rate of 6.5%.\n- Given the current share price of SEK182.7, the analyst price target of SEK221.67 is 17.6% higher.\n- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.\nHow well do narratives help inform your perspective?\nDisclaimer\nAnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material."
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/152/undiscovered-gems-with-strong-fundamentals/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014241",
      "text": "Results\n4655\nHigh-performing small cap companies that haven't yet garnered significant analyst attention, and could lead to superior returns.\n4655 companies\nAesler Grup Internasional\nMarket Cap: Rp3.7t\nProvides architectural and construction management services in Indonesia.\nRONY\nRp2,990.00\n7D\n0%\n1Y\n1,310.4%\nXinjiang Torch Gas\nMarket Cap: CN\u00a53.1b\nOperates as a gas service company in China.\n603080\nCN\u00a521.85\n7D\n-1.8%\n1Y\n67.4%\nShandong Sinoglory Health Food\nMarket Cap: CN\u00a52.3b\nManufactures soy proteins in China.\n603182\nCN\u00a514.20\n7D\n-0.2%\n1Y\n43.1%\nShanghai Material Trading\nMarket Cap: CN\u00a55.3b\nEngages in the wholesale and retail of production materials for automobile and chemicals in China and internationally.\n600822\nCN\u00a512.57\n7D\n4.8%\n1Y\n70.6%\nConcord Enviro Systems\nMarket Cap: \u20b911.4b\nEngages in the design, manufacture, installation, operation, and maintenance of industrial water and wastewater treatment, and reuse and zero liquid discharge systems and plants.\nCEWATER\n\u20b9550.50\n7D\n7.1%\n1Y\nn/a\nHangzhou Xili Intelligent TechnologyLtd\nMarket Cap: CN\u00a52.5b\nHangzhou Xili Intelligent Technology Co.,Ltd.\n688616\nCN\u00a514.24\n7D\n2.2%\n1Y\n76.0%\nRenxin New MaterialLtd\nMarket Cap: CN\u00a53.0b\nEngages in the research and development, production, and sale of polystyrene polymer materials in China.\n301395\nCN\u00a512.54\n7D\n2.7%\n1Y\n71.0%\nZHEJIANG DIBAY ELECTRICLtd\nMarket Cap: CN\u00a53.0b\nEngages in the research and development, production, and sale of sealed motors for household, commercial, and vehicle compressors in China and internationally.\n603320\nCN\u00a520.35\n7D\n4.7%\n1Y\n67.4%\nGuangdong Delian Group\nMarket Cap: CN\u00a54.1b\nEngages in the automobile fine chemicals, automobile sales service, and automobile repair and maintenance businesses, and development of new application scenarios in China.\n002666\nCN\u00a55.33\n7D\n2.7%\n1Y\n59.6%\nOriental Precision & EngineeringLtd\nMarket Cap: \u20a9298.3b\nOriental Precision & Engineering Co.,Ltd.\nA014940\n\u20a96,550.00\n7D\n-4.7%\n1Y\n57.1%\nYashima Denki\nMarket Cap: JP\u00a546.4b\nProvides plant business, industry/equipment, and transportation business in Japan and internationally.\n3153\nJP\u00a52,180.00\n7D\n8.7%\n1Y\n39.5%\nHind Rectifiers\nMarket Cap: \u20b928.4b\nDesigns, develops, manufactures, and markets power semiconductors, power electronic equipment, and railway transportation equipment in India and internationally.\n504036\n\u20b91,652.35\n7D\n-13.7%\n1Y\n71.6%\nJinsanjiang (Zhaoqing) Silicon Material\nMarket Cap: CN\u00a52.8b\nEngages in the research and development, production, and sale of precipitated silica.\n301059\nCN\u00a512.27\n7D\n1.1%\n1Y\n50.4%\nMinmetals Development\nMarket Cap: CN\u00a59.9b\nEngages in resource trading, metal trading, and supply chain services in China and internationally.\n600058\nCN\u00a59.22\n7D\n11.9%\n1Y\n55.0%\nTech Semiconductors\nMarket Cap: CN\u00a511.1b\nEngages in the development, manufacture, and sale of power semiconductor devices in China.\n300046\nCN\u00a546.93\n7D\n2.5%\n1Y\n202.8%\nManpowerGroup Greater China\nMarket Cap: HK$1.2b\nAn investment holding company, provides workforce solutions and services in the People\u2019s Republic of China, Hong Kong, Macau, and Taiwan.\n2180\nHK$5.70\n7D\n-0.9%\n1Y\n23.9%\nChongqing Chuanyi Automation\nMarket Cap: CN\u00a510.9b\nResearches, manufactures, and markets industrial auto-control systems and devices, and engineering integration services in China.\n603100\nCN\u00a521.38\n7D\n4.6%\n1Y\n33.8%\nZhubo Design\nMarket Cap: CN\u00a52.8b\nEngages in architectural design and consulting services in China.\n300564\nCN\u00a517.27\n7D\n0.3%\n1Y\n87.7%\nNanfang Ventilator\nMarket Cap: CN\u00a55.2b\nDesigns and manufactures HVAC products in China.\n300004\nCN\u00a510.75\n7D\n28.3%\n1Y\n166.1%\nHangzhou Fortune Gas Cryogenic Group\nMarket Cap: CN\u00a57.6b\nHangzhou Fortune Gas Cryogenic Group Co., Ltd.\n603173\nCN\u00a547.85\n7D\n5.8%\n1Y\n167.2%\nItafos\nMarket Cap: CA$572.0m\nOperates as a phosphate and specialty fertilizer company.\nIFOS\nCA$2.96\n7D\n0%\n1Y\n82.7%\nWholetech System Hitech\nMarket Cap: NT$9.4b\nProvides system integration services in Taiwan, China, and Singapore.\n3402\nNT$129.00\n7D\n4.0%\n1Y\n16.7%\nDaoming Optics&ChemicalLtd\nMarket Cap: CN\u00a56.2b\nEngages in the research and development, production, and sale of reflective materials and products worldwide.\n002632\nCN\u00a59.89\n7D\n5.1%\n1Y\n48.1%\nLelon Electronics\nMarket Cap: NT$14.0b\nDevelops, manufactures, markets, trades in, and sells electrolytic capacitors worldwide.\n2472\nNT$85.00\n7D\n2.2%\n1Y\n9.3%\nLi Ming Development Construction\nMarket Cap: NT$4.3b\nLi Ming Development Construction Co., Ltd.\n6212\nNT$41.95\n7D\n1.7%\n1Y\n-57.0%\nJiangsu Rainbow Heavy Industries\nMarket Cap: CN\u00a56.3b\nJiangsu Rainbow Heavy Industries Co., Ltd.\n002483\nCN\u00a57.10\n7D\n-0.8%\n1Y\n78.4%\nSuzhou Longjie Special Fiber\nMarket Cap: CN\u00a53.4b\nEngages in the research and development, production, and sale of polyester filaments in China and internationally.\n603332\nCN\u00a516.08\n7D\n13.1%\n1Y\n133.7%\nChina New City Group\nMarket Cap: HK$1.6b\nAn investment holding company, engages in the commercial property development and investment for leasing, and commercial operations in Mainland China and internationally.\n1321\nHK$0.85\n7D\n-12.4%\n1Y\n6.3%\nShanghai Chlor-Alkali Chemical\nMarket Cap: CN\u00a59.8b\nManufactures and sells chemical products in China and internationally.\n600618\nCN\u00a510.58\n7D\n3.5%\n1Y\n36.9%\nNeosem\nMarket Cap: \u20a9336.6b\nManufactures and sells semiconductor inspection equipment.\nA253590\n\u20a97,920.00\n7D\n-9.2%\n1Y\n-21.2%\nOuro Fino Sa\u00fade Animal Participa\u00e7\u00f5es\nMarket Cap: R$1.2b\nEngages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil.\nOFSA3\nR$22.22\n7D\n-4.8%\n1Y\n-2.1%\nTimex Group India\nMarket Cap: \u20b928.0b\nEngages in designing, manufacturing, and trading of watches in India and internationally.\n500414\n\u20b9277.60\n7D\n0.5%\n1Y\n82.7%\nJagsonpal Pharmaceuticals\nMarket Cap: \u20b915.7b\nEngages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally.\nJAGSNPHARM\n\u20b9235.05\n7D\n-4.1%\n1Y\n55.3%\nShenzhen Bsc TechnologyLtd\nMarket Cap: CN\u00a56.8b\nEngages in the design, development, production, and sale of functional devices for electronic products.\n300951\nCN\u00a540.27\n7D\n8.2%\n1Y\n55.5%\nSociete de Limonaderies et de Boissons Rafraichissantes d'Afrique\nMarket Cap: XOF 307.7b\nEngages in the manufacture and sale of beer, soft drinks, mineral water, alcomixes, and energy drink products.\nSLBC\nXOF 18,690.00\n7D\n5.9%\n1Y\nn/a\nLemtech Holdings\nMarket Cap: NT$5.2b\nResearch, develops, produces, and sells precision metal dies and metal stampings in Asia, the Americas, and Europe.\n4912\nNT$79.50\n7D\n-1.6%\n1Y\n-19.3%"
    },
    {
      "url": "https://simplywall.st/narratives/n8m7m79d-medical-and-engineered-solutions-will-open-new-markets-usi6?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
      "text": "Key Takeaways\n- Expansion into high-growth medical, electronics, and sustainable materials markets, supported by global capacity growth, is strengthening revenue prospects and operating margin outlook.\n- Investments in automation and efficiency, alongside rising demand for innovative and eco-friendly solutions, are boosting margin potential and earnings quality.\n- High CapEx for global expansion, overcapacity risks, and stagnating sales growth may constrain future margins and earnings, leaving Nolato vulnerable to market downturns.\nCatalysts\nAbout Nolato- Develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally.\n- Accelerating global healthcare expenditure and an aging population are fueling Nolato's Medical Solutions growth, underpinned by expansion into high-volume and high-margin segments like drug delivery systems and in-vitro diagnostics, supporting sustained increases in revenue and probable upward pressure on operating margins.\n- Rising electrification and connectivity trends-including wider adoption of 5G/6G and connected devices-are expanding demand for Nolato's advanced engineered solutions (e.g., EMC/antenna products), which, combined with Asian manufacturing expansion, creates opportunities for revenue growth and margin improvement as utilization increases.\n- Heightened customer preference and regulatory focus on sustainability is driving greater demand for Nolato's innovative bio-based and recyclable polymer offerings, enhancing future revenue streams and potentially allowing for higher-margin product mixes.\n- Ongoing investments in automation and operational efficiency (as evidenced by sequential margin improvement and targeted cost-outs) are reducing structural costs, directly supporting higher EBIT margins and improving overall earnings quality.\n- Recent and ongoing global capacity expansions (Hungary, Malaysia, Poland) backed by secured contracts with major clients are laying the groundwork for multi-year organic revenue growth and improved earnings visibility, with CapEx investments likely to yield positive operating leverage as new facilities ramp up.\nNolato Future Earnings and Revenue Growth\nAssumptions\nHow have these above catalysts been quantified?- Analysts are assuming Nolato's revenue will grow by 5.4% annually over the next 3 years.\n- Analysts assume that profit margins will increase from 7.7% today to 9.3% in 3 years time.\n- Analysts expect earnings to reach SEK 1.1 billion (and earnings per share of SEK 3.72) by about August 2028, up from SEK 738.0 million today.\n- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 20.3x on those 2028 earnings, down from 20.8x today. This future PE is lower than the current PE for the GB Industrials industry at 35.3x.\n- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.\n- To value all of this in today's terms, we will use a discount rate of 5.69%, as per the Simply Wall St company report.\nNolato Future Earnings Per Share Growth\nRisks\nWhat could happen that would invalidate this narrative?- High levels of CapEx related to global expansion (Hungary, Malaysia, Poland, and ongoing facility extensions) may not be fully offset by near-term revenue gains, leading to lower free cash flow and placing pressure on net margins and earnings if future demand is slower than anticipated.\n- Overcapacity issues, particularly in China and the U.S. (notably within the GW Plastics acquisition), highlight ongoing risks of underutilization, which can suppress profitability and slow further margin expansion, potentially impacting group EBIT margins and earnings.\n- Flat or single-digit organic sales growth (4%-5% even after currency adjustment) suggests the risk of growth stagnation as core markets, especially in Medical and Engineered Solutions, may reach saturation, which would limit revenue and long-term earnings growth.\n- Ongoing margin improvement has been broad-based and driven by cost-outs, efficiency gains, and pricing; however, management acknowledges that further margin gains may be harder to achieve from current levels, potentially capping future net margin and earnings growth.\n- Exposure to cyclical end-markets (Automotive, Consumer Electronics) and specific customer-driven expansions increases vulnerability to market downturns, contract losses, or slower adoption of new manufacturing sites, raising the risk of revenue volatility and margin compression.\nValuation\nHow have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of SEK67.25 for Nolato based on their expectations of its future earnings growth, profit margins and other risk factors.\n- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be SEK11.3 billion, earnings will come to SEK1.1 billion, and it would be trading on a PE ratio of 20.3x, assuming you use a discount rate of 5.7%.\n- Given the current share price of SEK57.05, the analyst price target of SEK67.25 is 15.2% higher.\n- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.\nHow well do narratives help inform your perspective?\nDisclaimer\nAnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material."
    },
    {
      "url": "https://simplywall.st/company/id/c6e8c454-220b-48fe-a82f-77a3a3417d63?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014241",
      "text": "Inwido (INWI) Stock Overview\nThrough its subsidiaries, engages in development, manufacture, and sale of windows and doors in Sweden. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 5/6 |\n| Future Growth | 1/6 |\n| Past Performance | 5/6 |\n| Financial Health | 6/6 |\n| Dividends | 4/6 |\nINWI Community Fair Values\nSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.\nInwido AB (publ) Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | SEK 190.00 |\n| 52 Week High | SEK 221.60 |\n| 52 Week Low | SEK 172.00 |\n| Beta | 1.2 |\n| 1 Month Change | 3.94% |\n| 3 Month Change | -10.71% |\n| 1 Year Change | 8.14% |\n| 3 Year Change | 79.08% |\n| 5 Year Change | 121.32% |\n| Change since IPO | 194.57% |\nRecent News & Updates\nInwido AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now\nJul 17Returns On Capital Are Showing Encouraging Signs At Inwido (STO:INWI)\nJun 19Should You Investigate Inwido AB (publ) (STO:INWI) At kr215?\nMay 30Recent updates\nInwido AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now\nJul 17Returns On Capital Are Showing Encouraging Signs At Inwido (STO:INWI)\nJun 19Should You Investigate Inwido AB (publ) (STO:INWI) At kr215?\nMay 30Inwido's (STO:INWI) Dividend Will Be Reduced To SEK5.50\nMay 07Inwido AB (publ) Just Missed EPS By 42%: Here's What Analysts Think Will Happen Next\nApr 28Inwido (STO:INWI) Will Pay A Smaller Dividend Than Last Year\nApr 23These 4 Measures Indicate That Inwido (STO:INWI) Is Using Debt Reasonably Well\nApr 01Returns On Capital At Inwido (STO:INWI) Have Stalled\nMar 19Are Investors Undervaluing Inwido AB (publ) (STO:INWI) By 42%?\nMar 06Expanding Acquisitions And Focus On EU Green Transition Will Strengthen Market Position By 2030\nInwido's strategic acquisitions and e-commerce focus are expected to bolster growth and market position by leveraging financial headroom and profitability improvements.Inwido (STO:INWI) Will Pay A Smaller Dividend Than Last Year\nFeb 09At kr188, Is Inwido AB (publ) (STO:INWI) Worth Looking At Closely?\nJan 21Inwido (STO:INWI) Might Have The Makings Of A Multi-Bagger\nNov 19Earnings Update: Inwido AB (publ) (STO:INWI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts\nOct 25These 4 Measures Indicate That Inwido (STO:INWI) Is Using Debt Reasonably Well\nAug 07Earnings Update: Here's Why Analysts Just Lifted Their Inwido AB (publ) (STO:INWI) Price Target To kr188\nJul 17The Return Trends At Inwido (STO:INWI) Look Promising\nJul 13Inwido (STO:INWI) Has Announced A Dividend Of SEK6.50\nMay 11Here's Why Inwido (STO:INWI) Can Manage Its Debt Responsibly\nNov 15Inwido (STO:INWI) Might Have The Makings Of A Multi-Bagger\nOct 25Inwido AB (publ)'s (STO:INWI) Intrinsic Value Is Potentially 72% Above Its Share Price\nSep 05Inwido's (STO:INWI) Upcoming Dividend Will Be Larger Than Last Year's\nApr 05Inwido (STO:INWI) Is Increasing Its Dividend To SEK6.50\nFeb 10A Look At The Fair Value Of Inwido AB (publ) (STO:INWI)\nFeb 08Does Inwido (STO:INWI) Have A Healthy Balance Sheet?\nDec 16With EPS Growth And More, Inwido (STO:INWI) Makes An Interesting Case\nNov 11Why Inwido AB (publ) (STO:INWI) Could Be Worth Watching\nSep 28Inwido (STO:INWI) Seems To Use Debt Quite Sensibly\nJul 22With EPS Growth And More, Inwido (STO:INWI) Makes An Interesting Case\nJul 10Is It Time To Consider Buying Inwido AB (publ) (STO:INWI)?\nJun 15Return Trends At Inwido (STO:INWI) Aren't Appealing\nJun 03Inwido's (STO:INWI) Shareholders Will Receive A Bigger Dividend Than Last Year\nApr 28Inwido (STO:INWI) Is Increasing Its Dividend To kr6.15\nApr 05Inwido (STO:INWI) Has Announced That It Will Be Increasing Its Dividend To kr6.15\nMar 03These 4 Measures Indicate That Inwido (STO:INWI) Is Using Debt Safely\nFeb 23Inwido (STO:INWI) Is Paying Out A Larger Dividend Than Last Year\nFeb 10Shareholder Returns\n| INWI | SE Building | SE Market | |\n|---|---|---|---|\n| 7D | 4.5% | 3.2% | 2.6% |\n| 1Y | 8.1% | -0.4% | 0.5% |\nReturn vs Industry: INWI exceeded the Swedish Building industry which returned -0.4% over the past year.\nReturn vs Market: INWI exceeded the Swedish Market which returned 0.5% over the past year.\nPrice Volatility\n| INWI volatility | |\n|---|---|\n| INWI Average Weekly Movement | 4.3% |\n| Building Industry Average Movement | 4.4% |\n| Market Average Movement | 5.7% |\n| 10% most volatile stocks in SE Market | 12.8% |\n| 10% least volatile stocks in SE Market | 3.1% |\nStable Share Price: INWI has not had significant price volatility in the past 3 months compared to the Swedish market.\nVolatility Over Time: INWI's weekly volatility (4%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1811 | 4,700 | Fredrik Meuller | www.inwido.com |\nInwido AB (publ), through its subsidiaries, engages in development, manufacture, and sale of windows and doors in Sweden. It operates through four segments: Scandinavia, Eastern Europe, e-Commerce, and Western Europe. The company offers wood, aluminum, and glass products; and fittings; indoor climate and safety, and related accessories and services.\nInwido AB (publ) Fundamentals Summary\n| INWI fundamental statistics | |\n|---|---|\n| Market cap | SEK 11.01b |\n| Earnings (TTM) | SEK 564.70m |\n| Revenue (TTM) | SEK 9.03b |\nIs INWI overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| INWI income statement (TTM) | |\n|---|---|\n| Revenue | SEK 9.03b |\n| Cost of Revenue | SEK 6.70b |\n| Gross Profit | SEK 2.34b |\n| Other Expenses | SEK 1.77b |\n| Earnings | SEK 564.70m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nOct 21, 2025\n| Earnings per share (EPS) | 9.74 |\n| Gross Margin | 25.89% |\n| Net Profit Margin | 6.25% |\n| Debt/Equity Ratio | 30.9% |\nHow did INWI perform over the long term?\nSee historical performance and comparisonDividends\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:44 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nInwido AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Kenneth Toll Johansson | Carnegie Investment Bank AB |\n| Henrik Christiansson | DNB Carnegie |\n| Rasmus Engberg | Handelsbanken Capital Markets |"
    },
    {
      "url": "https://simplywall.st/company/id/b12ff78b-cf2b-46c7-95bc-2dc07a9b1c31?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014241",
      "text": "Nolato (NOLA B) Stock Overview\nDevelops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 4/6 |\n| Future Growth | 2/6 |\n| Past Performance | 4/6 |\n| Financial Health | 5/6 |\n| Dividends | 4/6 |\nNOLA B Community Fair Values\nSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nNolato AB (publ) Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | SEK 58.50 |\n| 52 Week High | SEK 64.90 |\n| 52 Week Low | SEK 46.80 |\n| Beta | 0.85 |\n| 1 Month Change | -2.90% |\n| 3 Month Change | -0.76% |\n| 1 Year Change | 8.64% |\n| 3 Year Change | 7.04% |\n| 5 Year Change | -30.61% |\n| Change since IPO | 1,883.05% |\nRecent News & Updates\nGetting In Cheap On Nolato AB (publ) (STO:NOLA B) Is Unlikely\nAug 05Earnings Beat: Nolato AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models\nJul 22Some Investors May Be Worried About Nolato's (STO:NOLA B) Returns On Capital\nJun 14Recent updates\nGetting In Cheap On Nolato AB (publ) (STO:NOLA B) Is Unlikely\nAug 05Earnings Beat: Nolato AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models\nJul 22Some Investors May Be Worried About Nolato's (STO:NOLA B) Returns On Capital\nJun 14We Think Nolato (STO:NOLA B) Can Stay On Top Of Its Debt\nMay 26Nolato AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year\nMay 09Nolato's (STO:NOLA B) Dividend Will Be SEK1.50\nMay 06Are Investors Undervaluing Nolato AB (publ) (STO:NOLA B) By 34%?\nApr 30Some Confidence Is Lacking In Nolato AB (publ)'s (STO:NOLA B) P/E\nApr 17Nolato (STO:NOLA B) Is Due To Pay A Dividend Of SEK1.50\nApr 03Is It Too Late To Consider Buying Nolato AB (publ) (STO:NOLA B)?\nApr 01Nolato (STO:NOLA B) Is Paying Out A Dividend Of SEK1.50\nMar 05Focus On In-Vitro Diagnostics Will Strengthen Future Prospects In Medical Solutions\nNolato's transformation and innovation in Engineered Solutions enhance profit margins and could boost revenue through favorable product mixes.Analyst Estimates: Here's What Brokers Think Of Nolato AB (publ) (STO:NOLA B) After Its Full-Year Report\nFeb 11Why Investors Shouldn't Be Surprised By Nolato AB (publ)'s (STO:NOLA B) P/E\nJan 14The Nolato AB (publ) (STO:NOLA B) Third-Quarter Results Are Out And Analysts Have Published New Forecasts\nOct 28We Discuss Why Nolato AB (publ)'s (STO:NOLA B) CEO Compensation May Be Closely Reviewed\nApr 30Nolato's (STO:NOLA B) Dividend Is Being Reduced To SEK1.50\nApr 27Nolato (STO:NOLA B) Is Paying Out Less In Dividends Than Last Year\nApr 13Is It Too Late To Consider Buying Nolato AB (publ) (STO:NOLA B)?\nApr 04Nolato AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models\nFeb 09An Intrinsic Calculation For Nolato AB (publ) (STO:NOLA B) Suggests It's 45% Undervalued\nFeb 07Does Nolato (STO:NOLA B) Have A Healthy Balance Sheet?\nJan 07Shareholders Should Be Pleased With Nolato AB (publ)'s (STO:NOLA B) Price\nDec 24Is Nolato AB (publ) (STO:NOLA B) Potentially Undervalued?\nDec 09Is There An Opportunity With Nolato AB (publ)'s (STO:NOLA B) 39% Undervaluation?\nAug 18At kr44.40, Is Nolato AB (publ) (STO:NOLA B) Worth Looking At Closely?\nJul 26Nolato (STO:NOLA B) Seems To Use Debt Quite Sensibly\nJun 02Estimating The Intrinsic Value Of Nolato AB (publ) (STO:NOLA B)\nMay 19Returns On Capital Signal Tricky Times Ahead For Nolato (STO:NOLA B)\nMay 02Is It Too Late To Consider Buying Nolato AB (publ) (STO:NOLA B)?\nApr 19Is Nolato (STO:NOLA B) Using Too Much Debt?\nFeb 23Nolato (STO:NOLA B) Has Affirmed Its Dividend Of SEK1.90\nFeb 11A Look At The Fair Value Of Nolato AB (publ) (STO:NOLA B)\nJan 28When Should You Buy Nolato AB (publ) (STO:NOLA B)?\nJan 10Returns On Capital At Nolato (STO:NOLA B) Paint A Concerning Picture\nDec 06We Think Nolato (STO:NOLA B) Can Stay On Top Of Its Debt\nNov 09Are Investors Undervaluing Nolato AB (publ) (STO:NOLA B) By 47%?\nOct 16Does Nolato (STO:NOLA B) Deserve A Spot On Your Watchlist?\nSep 03Is Now The Time To Look At Buying Nolato AB (publ) (STO:NOLA B)?\nAug 22Shareholder Returns\n| NOLA B | SE Industrials | SE Market | |\n|---|---|---|---|\n| 7D | 4.2% | 1.6% | 2.2% |\n| 1Y | 8.6% | -4.3% | 0.6% |\nReturn vs Industry: NOLA B exceeded the Swedish Industrials industry which returned -4.3% over the past year.\nReturn vs Market: NOLA B exceeded the Swedish Market which returned 0.6% over the past year.\nPrice Volatility\n| NOLA B volatility | |\n|---|---|\n| NOLA B Average Weekly Movement | 3.5% |\n| Industrials Industry Average Movement | 5.5% |\n| Market Average Movement | 5.7% |\n| 10% most volatile stocks in SE Market | 12.8% |\n| 10% least volatile stocks in SE Market | 3.1% |\nStable Share Price: NOLA B has not had significant price volatility in the past 3 months compared to the Swedish market.\nVolatility Over Time: NOLA B's weekly volatility (4%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1938 | 5,522 | Christer Wahlquist | www.nolato.com |\nNolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. The company offers catheter balloons; breathing bags; non-conductive sealing and damping silicone products; primary plastic packaging for medicines; and crimp and dropper bottles.\nNolato AB (publ) Fundamentals Summary\n| NOLA B fundamental statistics | |\n|---|---|\n| Market cap | SEK 15.76b |\n| Earnings (TTM) | SEK 738.00m |\n| Revenue (TTM) | SEK 9.63b |\nIs NOLA B overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| NOLA B income statement (TTM) | |\n|---|---|\n| Revenue | SEK 9.63b |\n| Cost of Revenue | SEK 7.94b |\n| Gross Profit | SEK 1.70b |\n| Other Expenses | SEK 957.00m |\n| Earnings | SEK 738.00m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nOct 28, 2025\n| Earnings per share (EPS) | 2.74 |\n| Gross Margin | 17.60% |\n| Net Profit Margin | 7.66% |\n| Debt/Equity Ratio | 28.6% |\nHow did NOLA B perform over the long term?\nSee historical performance and comparisonDividends\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 03:29 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nNolato AB (publ) is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| null null | ABG Sundal Collier |\n| null null | ABG Sundal Collier Sponsored |\n| Mikael Las\u00e9en | Carnegie Investment Bank AB |"
    },
    {
      "url": "https://simplywall.st/narratives/94ufd831-abbvie-agreement-and-clinical-trials-will-unlock-new-avenues?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4014241",
      "text": "Last Update16 Aug 25Fair value Decreased 15%\nThe significant downward revision in Gubra\u2019s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540.\nWhat's in the News\n- Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.\n- Board proposed the extraordinary dividend in advance of the EGM.\n- Special/Extraordinary Shareholders Meeting held to discuss and approve the dividend distribution.\nValuation Changes\nSummary of Valuation Changes for Gubra\n- The Consensus Analyst Price Target has significantly fallen from DKK635.00 to DKK540.00.\n- The Future P/E for Gubra has fallen from 15.83x to 14.89x.\n- The Consensus Revenue Growth forecasts for Gubra has fallen from 49.1% per annum to 46.5% per annum.\nKey Takeaways\n- Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.\n- Promising clinical trial results and innovative treatments could boost future revenue and market position in weight management and obesity treatments.\n- Revenue and profitability are at risk due to dependency on partnerships, increased costs, and challenges in strategic expansion and execution.\nCatalysts\nAbout Gubra- A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\n- The landmark agreement with AbbVie grants Gubra significant economic freedom with a $350 million upfront payment and potential milestones worth $1.875 billion, along with tiered royalties on net sales. This is likely to boost Gubra's future revenue and earnings.\n- The successful interim data from the GUBamy trial, showing substantial weight loss in patients, could position GUBamy as a best-in-class weight management treatment. This may lead to increased future revenue through sales and potential market expandability.\n- The UCN2 program's promising results in altering body composition by promoting fat loss while preserving lean muscle mass indicate potential differentiation from other obesity treatments. This could enhance future earnings through new product offerings and market capture.\n- Gubra's strategic relationships with 16 out of the top 20 pharma companies and the ongoing partnerships, including 7 active collaborations, should provide sustainable revenue streams and collaborative growth opportunities.\n- The maintained and expected growth in the CRO business, particularly strong demand in Europe, suggests a potential increase in future revenue, despite current slight declines, by expanding service offerings and leveraging existing client relationships.\nGubra Future Earnings and Revenue Growth\nAssumptions\nHow have these above catalysts been quantified?- Analysts are assuming Gubra's revenue will grow by 49.1% annually over the next 3 years.\n- Analysts assume that profit margins will increase from -13.7% today to 85.0% in 3 years time.\n- Analysts expect earnings to reach DKK 749.0 million (and earnings per share of DKK 11.22) by about August 2028, up from DKK -36.5 million today. The analysts are largely in agreement about this estimate.\n- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 15.8x on those 2028 earnings, up from -155.4x today. This future PE is lower than the current PE for the DK Life Sciences industry at 50.8x.\n- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.\n- To value all of this in today's terms, we will use a discount rate of 5.28%, as per the Simply Wall St company report.\nGubra Future Earnings Per Share Growth\nRisks\nWhat could happen that would invalidate this narrative?- The slight decline in CRO business revenue indicates a potential risk in maintaining or growing revenue from this segment, especially if longer decision times from U.S.-based companies persist or increase. This could impact overall revenue stability.\n- The significant upfront payment and potential future milestones from the AbbVie deal imply dependency on this partnership for financial gains. Any setbacks in this partnership could jeopardize expected earnings from these milestones and royalties.\n- Increased costs due to simultaneous program developments for Amylin and UCN2 may pressure net margins, particularly if these programs face delays or require added investment without immediate return.\n- The CRO business experienced a decline in EBIT, indicating potential struggles with maintaining profitability amidst rising fixed costs, such as salaries, which may affect net margins if revenue growth does not outpace cost increases.\n- The ongoing need to evaluate M&A opportunities and explore expansion areas suggests the company might face strategic execution risks. These risks could impact the effective allocation of capital and ultimately affect future earnings if these ventures do not yield expected returns.\nValuation\nHow have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of DKK635.0 for Gubra based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK750.0, and the most bearish reporting a price target of just DKK520.0.\n- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be DKK881.3 million, earnings will come to DKK749.0 million, and it would be trading on a PE ratio of 15.8x, assuming you use a discount rate of 5.3%.\n- Given the current share price of DKK347.8, the analyst price target of DKK635.0 is 45.2% higher.\n- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.\nHow well do narratives help inform your perspective?\nDisclaimer\nAnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material."
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global?utm_medium=finance_user&utm_campaign=conclusion-grid&utm_source=yahoo&blueprint=4014241",
      "text": "Results\n860\nCompanies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.\n860 companies\nAmbipar Participa\u00e7\u00f5es e Empreendimentos\nMarket Cap: R$22.3b\nAmbipar Participa\u00e7\u00f5es e Empreendimentos S.A.\nAMBP3\nR$13.40\n7D\n-4.8%\n1Y\n45.9%\nKolmar Korea\nMarket Cap: \u20a91.9t\nResearches, develops, produces, and sells beauty and health products in South Korea and internationally.\nA161890\n\u20a979,100.00\n7D\n-0.8%\n1Y\n12.8%\nWELL Health Technologies\nMarket Cap: CA$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWELL\nCA$4.92\n7D\n-1.6%\n1Y\n6.5%\nBloomberry Resorts\nMarket Cap: \u20b141.0b\nThrough its subsidiaries, develops, owns, and operates hotels, casinos, and integrated resorts in the Philippines and Korea.\nBLOOM\n\u20b13.57\n7D\n-0.8%\n1Y\n-53.6%\nS Chand\nMarket Cap: \u20b97.0b\nS Chand and Company Limited, an education content company, develops and delivers content, solutions, and services for the early learning, K-12, and higher education segments in India.\nSCHAND\n\u20b9197.85\n7D\n1.9%\n1Y\n-14.2%\nWanguo Gold Group\nMarket Cap: HK$32.0b\nAn investment holding company, engages in mining, ore processing, and sale of concentrate products in the People\u2019s Republic of China and Solomon Islands.\n3939\nHK$29.50\n7D\n-16.2%\n1Y\n282.1%\nEROAD\nMarket Cap: NZ$434.0m\nProvides electronic on-board units and software as a service to the transport industry in New Zealand, the United States, and Australia.\nERD\nNZ$2.32\n7D\n0.4%\n1Y\n78.5%\nSavaria\nMarket Cap: CA$1.5b\nProvides accessibility solutions for the elderly and physically challenged people in Canada, the United States, Europe, and internationally.\nSIS\nCA$21.15\n7D\n0.5%\n1Y\n5.6%\nWix.com\nMarket Cap: US$7.4b\nOperates a cloud-based web development platform for registered users and creators worldwide.\nWIX\nUS$131.82\n7D\n2.4%\n1Y\n-20.6%\nKeePer Technical Laboratory\nMarket Cap: JP\u00a594.0b\nDevelops, manufactures, and sells car coatings, car washing chemicals and equipment, and other products in Japan.\n6036\nJP\u00a53,445.00\n7D\n-1.3%\n1Y\n-7.9%\nNorconsult\nMarket Cap: NOK 14.2b\nProvides consultancy services with focus on community planning, engineering design, and architecture in the Nordics and internationally.\nNORCO\nNOK 45.80\n7D\n6.9%\n1Y\n32.9%\nCosmax\nMarket Cap: \u20a92.4t\nResearches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally.\nA192820\n\u20a9213,000.00\n7D\n12.0%\n1Y\n75.5%\nMatsuya R&DLtd\nMarket Cap: JP\u00a515.4b\nDevelops, manufactures, and sells stitching systems for automobile safety devices in Japan.\n7317\nJP\u00a5720.00\n7D\n2.1%\n1Y\n9.4%\nCorporativo Fragua. de\nMarket Cap: Mex$51.3b\nOperates pharmacy stores under the Superfarmacia name in Mexico.\nFRAGUA B\nMex$536.00\n7D\n-0.6%\n1Y\n-48.4%\nUWC Berhad\nMarket Cap: RM 3.0b\nAn investment holding company, engages in the provision of precision sheet metal fabrication, precision machined components, and value-added assembly services.\nUWC\nRM 2.71\n7D\n-1.5%\n1Y\n0.7%\nHillgrove Resources\nMarket Cap: AU$96.7m\nEngages in the operation, exploration, and development of mineral properties in Australia.\nHGO\nAU$0.037\n7D\n5.7%\n1Y\n-33.9%\nInvestar Holding\nMarket Cap: US$230.2m\nOperates as the bank holding company for Investar Bank that provides a range of commercial banking products to individuals, professionals, and small to medium-sized businesses in south Louisiana, southeast Texas, and Alabama in the United States.\nISTR\nUS$23.42\n7D\n6.4%\n1Y\n27.8%\nFaraday Technology\nMarket Cap: NT$38.8b\nOperates as a fabless ASIC/SoC and silicon intellectual property (IP) provider in China, Taiwan, Japan, the United States, and internationally.\n3035\nNT$149.00\n7D\n-2.9%\n1Y\n-49.8%\nJiangxi Rimag Group\nMarket Cap: HK$7.0b\nInvests and operates medical imaging centers in China.\n2522\nHK$19.11\n7D\n-18.0%\n1Y\n5.1%\nSolarEdge Technologies\nMarket Cap: US$2.0b\nDesigns, develops, manufactures, and sells direct current (DC) optimized inverter systems for solar photovoltaic (PV) installations in the United States, Germany, the Netherlands, Italy, rest of Europe, and internationally.\nSEDG\nUS$34.30\n7D\n10.1%\n1Y\n31.3%\nATON Green Storage\nMarket Cap: \u20ac15.6m\nEngages in the production and sale of storage systems for photovoltaic systems and battery energy storage system.\nATON\n\u20ac2.08\n7D\n1.0%\n1Y\n-64.4%\nHypera\nMarket Cap: R$15.0b\nOperates as a pharmaceutical company in Brazil.\nHYPE3\nR$23.75\n7D\n4.1%\n1Y\n-23.5%\nReckon\nMarket Cap: AU$68.5m\nProvides software solutions in Australia, New Zealand, the United States, and internationally.\nRKN\nAU$0.60\n7D\n-4.0%\n1Y\n18.6%\nSunjin Beauty ScienceLtd\nMarket Cap: \u20a9128.1b\nSUNJIN BEAUTY SCIENCE Co. ,Ltd. researches, develops, manufactures, and exports cosmetics, surfactant, and polymer bead products.\nA086710\n\u20a910,670.00\n7D\n-4.4%\n1Y\n-3.8%\nPeapack-Gladstone Financial\nMarket Cap: US$498.5m\nOperates as the bank holding company for Peapack Private Bank & Trust that provides private banking and wealth management services in the United States.\nPGC\nUS$28.46\n7D\n7.2%\n1Y\n1.2%\nABO Energy GmbH KGaA\nMarket Cap: \u20ac337.5m\nDevelops renewable energy projects in Germany and internationally.\nAB9\n\u20ac36.60\n7D\n-4.4%\n1Y\n-21.8%\nMetropolitan Bank Holding\nMarket Cap: US$801.6m\nOperates as the bank holding company for Metropolitan Commercial Bank that provides a range of business, commercial, and retail banking products and services.\nMCB\nUS$76.92\n7D\n5.4%\n1Y\n47.6%\nAquila Part Prod Com\nMarket Cap: RON 1.7b\nProvides distribution and logistics services in Romania, Moldova, Poland, the Netherlands, Germany, and internationally.\nAQ\nRON 1.46\n7D\n1.3%\n1Y\n3.8%\nRobit Oyj\nMarket Cap: \u20ac24.4m\nEngages in the design, manufacture, and sale of drilling consumables for mining, quarrying, construction, and well drilling industries in Finland.\nROBIT\n\u20ac1.16\n7D\n-3.3%\n1Y\n-31.4%\nLATAM Airlines Group\nMarket Cap: CL$13.7t\nProvides passenger and cargo air transportation services in Chile, Argentina, Peru, Colombia, Ecuador, Brazil, the United States, other Latin American countries, the Caribbean, Europe, and Oceania.\nLTM\nCL$23.09\n7D\n9.0%\n1Y\n96.2%\nHonkarakenne Oyj\nMarket Cap: \u20ac16.9m\nDesigns, manufactures, and sells log and solid-wood house packages in Finland.\nHONBS\n\u20ac2.87\n7D\n4.0%\n1Y\n-0.3%\nApotea\nMarket Cap: SEK 11.2b\nOperates an online pharmacy in Sweden.\nAPOTEA\nSEK 107.22\n7D\n-4.1%\n1Y\nn/a\nAtea\nMarket Cap: NOK 16.3b\nProvides IT infrastructure and related solutions for businesses and public sector organizations in the Nordic countries and Baltic regions.\nATEA\nNOK 146.20\n7D\n1.2%\n1Y\n1.4%\nSRE Holdings\nMarket Cap: JP\u00a549.4b\nEngages in the AI cloud and consulting, and real estate tech businesses in Japan.\n2980\nJP\u00a53,070.00\n7D\n-5.4%\n1Y\n-33.0%\nCustomers Bancorp\nMarket Cap: US$2.2b\nOperates as the bank holding company for Customers Bank that provides banking products and services.\nCUBI\nUS$68.72\n7D\n4.3%\n1Y\n34.7%\nAustal\nMarket Cap: AU$2.9b\nEngages in the design, manufacture, and support of vessels for commercial and defense customers worldwide.\nASB\nAU$6.81\n7D\n0.7%\n1Y\n204.0%"
    },
    {
      "url": "https://simplywall.st/company/id/54c067c3-08bf-4afb-8a2f-7d967c43d1ae?utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo&blueprint=4014241",
      "text": "Gubra (GUBRA) Stock Overview\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 3/6 |\n| Future Growth | 0/6 |\n| Past Performance | 4/6 |\n| Financial Health | 6/6 |\n| Dividends | 0/6 |\nRewards\nRisk Analysis\nGUBRA Community Fair Values\nSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.\nGubra A/S Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | DKK 373.00 |\n| 52 Week High | DKK 748.00 |\n| 52 Week Low | DKK 318.40 |\n| Beta | 0.68 |\n| 1 Month Change | -8.98% |\n| 3 Month Change | -6.61% |\n| 1 Year Change | -32.67% |\n| 3 Year Change | n/a |\n| 5 Year Change | n/a |\n| Change since IPO | 239.09% |\nRecent News & Updates\nRecent updates\nGubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors\nJun 28AbbVie Agreement And Clinical Trials Will Unlock New Avenues\nStrategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn\nMay 04Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio\nMar 11We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate\nJan 14Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up\nJun 19Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%\nMar 07Shareholder Returns\n| GUBRA | DK Life Sciences | DK Market | |\n|---|---|---|---|\n| 7D | 3.6% | 1.3% | 3.3% |\n| 1Y | -32.7% | -4.9% | -37.1% |\nReturn vs Industry: GUBRA underperformed the Danish Life Sciences industry which returned -4.9% over the past year.\nReturn vs Market: GUBRA exceeded the Danish Market which returned -37.1% over the past year.\nPrice Volatility\n| GUBRA volatility | |\n|---|---|\n| GUBRA Average Weekly Movement | 8.4% |\n| Life Sciences Industry Average Movement | 6.3% |\n| Market Average Movement | 4.4% |\n| 10% most volatile stocks in DK Market | 8.6% |\n| 10% least volatile stocks in DK Market | 2.3% |\nStable Share Price: GUBRA's share price has been volatile over the past 3 months compared to the Danish market.\nVolatility Over Time: GUBRA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Danish stocks.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2008 | 275 | Henrik Blou | www.gubra.dk |\nGubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology.\nGubra A/S Fundamentals Summary\n| GUBRA fundamental statistics | |\n|---|---|\n| Market cap | DKK 6.10b |\n| Earnings (TTM) | DKK 1.75b |\n| Revenue (TTM) | DKK 2.64b |\nIs GUBRA overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| GUBRA income statement (TTM) | |\n|---|---|\n| Revenue | DKK 2.64b |\n| Cost of Revenue | DKK 96.02m |\n| Gross Profit | DKK 2.54b |\n| Other Expenses | DKK 794.73m |\n| Earnings | DKK 1.75b |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nFeb 27, 2026\n| Earnings per share (EPS) | 106.86 |\n| Gross Margin | 96.36% |\n| Net Profit Margin | 66.22% |\n| Debt/Equity Ratio | 0% |\nHow did GUBRA perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 05:17 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nGubra A/S is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Rune Dahl | DNB Carnegie |\n| Jesper Ils\u00f8e | DNB Carnegie |\n| Rajan Sharma | Goldman Sachs |"
    }
  ],
  "argos_summary": "European markets are posting modest gains as investors hunt for growth opportunities, spotlighting companies like Gubra A/S, a biotech with a dramatic earnings turnaround and a lucrative partnership with AbbVie, and Swedish firms Inwido and Nolato, which are praised for their solid fundamentals and potential upside. Gubra\u2019s valuation has been revised upward after strong financials and promising clinical trials, while Inwido and Nolato are noted for their healthy balance sheets, dividend policies, and strategic acquisitions aimed at expanding market share. The narrative emphasizes the attractiveness of these \u201cundiscovered gems\u201d amid a backdrop of lower U.S. borrowing costs and rising business activity across Europe.",
  "argos_id": "QUR0Z7I5M"
}